Morri Mattia, Boccomino Riccardo, Brruku Eugenio, Romagnoli Erika, Boschi Rita, Raucci Giovanni, Bellina Terra Ausilia, Coluccino Paola
IRCCS Istituto Ortopedico Rizzoli, Servizio di Assistenza Infermieristico, Tecnico e della Riabilitazione (SAITeR), via G.C.Pupilli, 1, 40136, Bologna, Italy.
IRCCS Istituto Ortopedico Rizzoli, Servizio di Assistenza Infermieristico, Tecnico e della Riabilitazione (SAITeR), via G.C.Pupilli, 1, 40136, Bologna, Italy.
Eur J Oncol Nurs. 2025 Feb;74:102736. doi: 10.1016/j.ejon.2024.102736. Epub 2024 Nov 16.
the aim of the study is to evaluate the presence of fatigue syndrome, the quality of life and functional ability of patients with bone and soft tissue sarcomas during the first 6 months of chemotherapy and identify possible prognostic factors.
prospective observational study was conducted. All patients about to start chemotherapy were consecutively recruited from July 2019 to April 2021. Patient fatigue, quality of life was measured at the start of chemotherapy and after 6 months. BFI score and EORTC QLQ C-30 was used respectively.
The analysis of risk factors was performed on 98 patients. According to BFI score, in 36% of patients fatigue was classified from moderate to severe. The average global quality of life and TESS score increased by 3.9 and 8.5 points respectively. The strength of the association between the BFI score and EORTC subscales and TESS score was moderate (p < 0.001). Smoking status, higher BMI and impaired functional capabilities were independent predictive factors of fatigue.
Fatigue syndrome is present in a significant percentage of patients both at the start of chemotherapy treatment and in the following 6 months. Being a no smoker, higher BMI and impaired functional ability could impact fatigue syndrome. Fatigue screening, patient education and adapted aerobic exercise should be encouraged from the beginning of chemotherapy treatment. The quality of life and functional ability are associated with fatigue syndrome. REGISTRATION NUMBER (CLINICALTRIAL.GOV): NCT04104750 (26/09/2019).
本研究旨在评估骨肉瘤和软组织肉瘤患者在化疗的前6个月中疲劳综合征的存在情况、生活质量和功能能力，并确定可能的预后因素。
进行了一项前瞻性观察研究。2019年7月至2021年4月连续招募了所有即将开始化疗的患者。在化疗开始时和6个月后测量患者的疲劳程度和生活质量。分别使用BFI评分和EORTC QLQ C-30量表。
对98例患者进行了危险因素分析。根据BFI评分，36%的患者疲劳程度被分类为中度至重度。总体生活质量平均提高了3.9分，TESS评分平均提高了8.5分。BFI评分与EORTC分量表和TESS评分之间的关联强度为中度（p<0.001）。吸烟状况、较高的体重指数和功能能力受损是疲劳的独立预测因素。
在化疗治疗开始时以及随后的6个月中，相当比例的患者存在疲劳综合征。不吸烟、较高的体重指数和功能能力受损可能会影响疲劳综合征。应从化疗治疗开始就鼓励进行疲劳筛查、患者教育和适当的有氧运动。生活质量和功能能力与疲劳综合征相关。注册号（CLINICALTRIAL.GOV）：NCT04104750（2019年9月26日）。
